



Biomarkers of exposure in urine of active smokers, non-smokers, and vapers

D. Gallart-Mateu¹ · P. Dualde² · C. Coscollà² · J. M. Soriano³ · S. Garrigues¹ · M. de la Guardia¹

Received: 19 July 2023 / Revised: 5 September 2023 / Accepted: 6 September 2023
© The Author(s) 2023

Abstract

The exposure to smoking related products has been evaluated through urine illness risk marker determination through the analysis of urine samples of smokers and vapers. Biomarkers and their metabolites such as *N*-acetyl-*S*-(2-cyanoethyl)-*L*-cysteine (CEMA), *N*-acetyl-*S*-(3,4-dihydroxybutyl)-*L*-cysteine (DHBMA), *N*-acetyl-*S*-[1-(hydroxymethyl)-2-propen-1-yl]-*L*-cysteine (MHBMA), *N*-acetyl-*S*-(3-hydroxypropyl)-*L*-cysteine (3HPMA), 2*R*-*N*-acetyl-*S*-(4-hydroxybutan-2-yl)-*L*-cysteine (HMPMA), and *N*-acetyl-*S*-(3-carboxy-2-propyl)-*L*-cysteine (CMEMA) together with nicotine and cotinine were identified and quantified by LC-HRMS and LC-MS/MS, and data found normalized to the creatinine level. One hundred two urine samples were collected from smokers, non-smokers, and vapers, spanning an age range from 16 to 79 years. Results obtained showed that CEMA was only detected in urine samples from smokers and MHBMA was in the same order of magnitude in all the urine samples analyzed. HMPMA was found in the urine of vapers at the same order of concentration as in non-smokers. 3HPMA in vapers was lower than in the urine of smokers, presenting an intermediate situation between smokers and non-smokers. On the other hand, DHBMA in vapers can reach similar values to those found for smokers, while CMEMA shows concentrations in the urine of vapers higher than in the case of non-smokers and traditional smokers, requiring new research to link this metabolite to the use of electronic cigarettes and possible alternative metabolomic routes. In general, this study seems to verify that traditional smoking practice constitutes a major source of carcinogenic chemicals compared with substitutive practices, although those practices are not free of potential harm.

Keywords Smoker and vaper · Urine · Biomarker · E-cigarette · Organic compounds · Nicotine

Introduction

Tobacco use, as a traditional practice in many countries around the world, is the main cause of death estimated for eight million people each year [1], and, in the case of Spain, it is estimated 69,000 deaths/year due to smoking [2]. Although the harmful effects of smoking are almost universally known, there were 933 million smokers worldwide in

2015. More than 80% of the world's smokers live in low- and middle-income countries [3]. It is estimated that about two-thirds of lung cancer deaths worldwide are due to smoking [4]. Smoking is also a cause of cancers of the oral cavity, pharynx, larynx, esophagus, nasal cavity, pancreas, bladder, stomach, liver, kidney, ureter, cervix, colorectum, and ovary (mucinous), as well as myeloid leukemia [5, 6].

The smoking addiction results from the rapid delivery of nicotine to the brain, leading to its highly reinforcing effects [5]. However, the devastating effects of burning tobacco are associated to the combustion products. Responding to this situation, in the last decade, there has been an explosion of alternative smokeless tobacco products as alternative to traditional tobacco, such as electronic cigarettes or heat not burn tobacco products. However, research articles reporting the composition of the generated aerosols by this type of devices have evidenced the presence of toxic compounds, such as carbonyl compounds, tobacco-specific nitrosamines (TSNAs), acrolein,

✉ M. de la Guardia
miguel.delaguardia@uv.es

¹ Department of Analytical Chemistry, University of Valencia, Research Building, 50 Dr. Moliner Street, 16100-Burjassot, Valencia, Spain

² Foundation for the Promotion of Health and Biomedical Research in the Valencian Region, FISABIO-Public Health, Av. Catalunya, 21, 46020 Valencia, Spain

³ GISP Grup d'Investigació en Salut Pública, Universitat Politècnica de Catalunya, Barcelona, Spain

or acrylamide [7–11]. In the same way, toxics have been reported in vaping liquids of electronic cigarettes [9, 12, 13]. Although the presence of nicotine in the aerosol generated at low temperature in electronic cigarettes is considerable [7], the amount of toxins and carcinogens is lower when compared to traditional tobacco smoke [14]. Despite of this, some studies have reported cancer disease development due to the exposure to electronic cigarettes in animals [15] or DNA damage on electronic cigarette consuming [16].

On the other hand, long-term exposure to some environmental, occupational, and non-occupational toxicants, such as benzene, toluene, styrene, 1,3-butadiene, and acrylamide, has adverse health effects, including the development of cancer [17–22].

Tobacco smoke, and in the same way the e-cigarettes aerosols, is a relevant non-occupational source of exposure [6, 23]. The main component of tobacco smoke use to be nicotine, which is primarily metabolized to cotinine in the human liver via CYP2A6 [24, 25]. Cotinine, the main metabolite of nicotine [26], is often used as a biomarker of tobacco exposure in humans [27–30] due to its higher concentration in blood (250–300 vs 10–50 ng/mL) and longer residence time than nicotine (16 vs 2 h) [27, 31]. However, the organism metabolizes the toxic compounds present in the smoke/vaping aerosols. Following inhalation, toxic compounds present in the smoke may undergo initial biotransformation (phase I metabolism) in the liver, to active, oxygenated, electrophilic intermediates, primarily due to oxidative action of cytochrome P450 enzymes. These intermediates are believed to be reactive species able of reacting with DNA and responsible for the genotoxicity associated with the parent compounds and subjected to the “mercapturic acid pathway” (phase II metabolism). During this biotransformation, catalyzed by the enzyme glutathione transferase, the electrophilic compound is deactivated by conjugation with glutathione, an endogenous tripeptide made up of glutamic acid, cysteine, and glycine. By means of other enzymatic reactions, the glutamic acid and, subsequently, the glycine are removed. The remaining cysteine conjugate is N-acetylated and eventually excreted in the urine as mercapturic acid [32, 33]. Thus, urinary mercapturic acids may be useful for assessing exposure to toxicants from both traditional tobacco and smokeless tobacco devices as well as many other exposure sources [32, 34].

Taking into account the aforementioned factors, the aim of this work concerns the comparison of some specific acrolein, acrylonitrile, benzene, and crotonaldehyde metabolite concentrations in urine, cited in literature as health risk markers [35] together with nicotine and cotinine in both, users of traditional burn tobacco and former smokers using vaping systems. Non-smokers urine was employed also as reference.

Material and methods

Reagents, standards, and samples

N-acetyl-S-(2-cyanoethyl)-L-cysteine ammonium salt >98% (CEMA, CAS: 74514-75-3), N-acetyl-S-(3,4-dihydroxybutyl)-L-cysteine mixture of diastereomers >95% (DHBMA, CAS: 144889-50-9), and (R,S)-N-acetyl-S-[1-(hydroxymethyl)-2-propen-1-yl]-L-cysteine + (R,S)-N-acetyl-S-(2-hydroxy-3-buten-1-yl)-L-cysteine 1:1 mixture >95% (MHBMA, CAS: mixture of 144889-51-0 and 159092-64-5) were obtained from Toronto Research Chemicals (Toronto, ON, Canada). N-acetyl-S-(3-hydroxypropyl)-L-cysteine sodium salt >98% (3HPMA, CAS: 14369-42-7), 2R-N-acetyl-S-(4-hydroxybutan-2-yl)-L-cysteine mixture of diastereomers >95% (HMPMA, CAS: 33164-64-6), and N-acetyl-S-(3-carboxy-2-propyl)-L-cysteine disodium salt mixture of diastereomers >98% (CMEMA, CAS: 1041285-62-4) were obtained from TLC Pharmaceutical Standards (New Market, ON, Canada). (-)-Nicotine >99% from Sigma-Aldrich (St. Louis, MO, USA) and 1 mg mL⁻¹ cotinine standard solution in methanol from Cerilliant Corporation (Round Rock, TX, USA) were employed. On the other side, 100 µg mL⁻¹ nicotine-d₄ standard solution in acetonitrile from Sigma-Aldrich (St. Louis, MO, USA) was used as nicotine and cotinine internal standard. Terfenadine and Val-Tyr-Val from Sigma Life Sciences (St. Louis, MO, USA), triallyl phosphite from Alfa Aesar Thermo Fischer (Kandel, Germany) and sulfaguanidine, sulfadimethoxine, reserpine, caffeine, and acetaminophen obtained from Sigma-Aldrich (St. Louis, MO, USA) were employed as internal standards for LC-MS/MS in metabolite determination.

Acrylonitrile (≥ 98%) provided by Sigma-Aldrich (St. Louis, MO, USA) and crotonaldehyde (>99%) mixture of isomers from Merck (Darmstadt, Germany) were employed in the volatile compounds experimental part. Toluene-d₈ (>99.9%) from Sigma-Aldrich (St. Louis, MO, USA) and acetonitrile for GC trace residue analysis (≥ 99.9%) from Scharlau (Barcelona, Spain) were employed as internal standards.

Methanol (LC-MS grade), acetonitrile (LC-MS quality), and the buffer constituents, acetic acid and ammonium formate, were provided by VWR Chemicals (Radnor, PA, USA) and Scharlau (Barcelona, Spain). Water employed with a maximum resistivity of 18.2 MΩ was obtained from a Milli-Q Millipore system (Bedford, MA, USA).

Sterile flasks were used to collect the first morning urine samples of 102 non-affected by renal affections subjects, including 14 smokers, 25 non-smokers, and 63 declared vapers to determine the presence and quantify the target metabolites. Candidates, men and women aged

between 16 and 79 years were selected taking into account their former smoking practice and present vaping habits. In general, volunteers smoked for 4–30 years before move to vaping and used vaping systems during the last 4 to 146 months. In all cases, the donors were informed of the objective of the study, and each volunteer was provided with an informed consent document including a confidentiality agreement between the university and the participants.

Once the samples were received, aliquots of 10 mL were taken and together with the original samples were frozen until analysis.

Sample population

Sampling process was performed according the guidelines of the ethics committee of the University of Valencia, verification code X0H21EQATBAG6TVF (see Figure S1). Table S1 indicates the characteristics of 102 subjects included in this study. As can be seen, a set of 51 male and 51 female was considered, spanning the age range from 20 to 78 years for men and from 16 to 75 years for women. Urine samples were obtained from 63 vapers (35 male and 28 female), 14 smokers (6 male and 7 female), and 25 non-smokers (9 male and 16 female) as control group. Creatinine values, obtained by the Jaffé reaction, were employed to normalize the urinary biomarker levels. It was found creatinine data which varied from 0.31 to 2.83 g L⁻¹_{urine}, being in concordance with levels found in literature for healthy individuals [34]. However, the creatinine reference approach is not advocated for urine samples with very low (< 0.3 g/l) or high (> 3 g/l) concentrations. Only for three samples, the creatinine contents were higher than 3 g L⁻¹ as it has been noticed in Table S1.

Creatinine analysis

Creatinine was used to normalize the data of target analytes in order to minimize the effect of characteristics and habits of the volunteers. Creatinine determination in urine samples was performed using a Linear Kroma autoanalyzer (Holliston, MA, USA). The analysis methodology is based on the colorimetric determination of creatinine using a urine volume of 20 µL by formation of a chromogen (the Janovsky complex) by reaction with alkaline picrate through the Jaffé reaction [36]. The employed methodology allowed the determination of creatinine in urine samples down to concentrations of 0.01 g L⁻¹.

LC-MS/MS procedure

Nicotine and cotinine determination in samples

Sample analysis was performed using a Thermo Scientific (Waltham, MA, USA) Vanquish UHPLC chromatograph

with a Thermo Scientific (Waltham, MA, USA) TSQ Altis triple quadrupole mass detector. For the separation of the analytes, a Hypersil GOLD C18 column, 1.9 µm (150 × 2.1 mm), provided by Thermo Scientific (Waltham, MA, USA), was used, together with a gradient method with two mobile phases, one of 0.1% acetic acid in ultrapure water (A) and another of 0.1% acetic acid in LC-MS grade MeOH (B). A 0.3 mL min⁻¹ constant flow was applied. In order to perform the chromatography separation, the following gradient program was used: at the initial time, the mobile phase composition was 90% (A) decreasing till 75 % (A) at 6 min, increasing till 90 % (A) at 6.5 min, and maintaining these conditions till the end of the chromatogram (10 min).

The detection of the analytes was carried out using positive ionization (ESI⁺) and applying a voltage of 3500 V. The column temperature was set at 35°C, the injections were measured in cycles of 0.8 s, and the injection volume was 10 µL. The m/z transitions used for the identification and quantification of the analytes were those indicated in Table S2.

For quantification of nicotine and cotinine, a concentrated multicomponent solution in methanol was prepared with the commercial standards. Calibration solutions were prepared in the concentration range of 190–3800 ng mL⁻¹ in the case of nicotine and 150–3000 ng mL⁻¹ in the case of cotinine. The calibration curve was prepared by adding 100 µL of urine (urine blank), 10 µL (2000 ng mL⁻¹) of internal standard, and an appropriate volume of multicomponent standard solution, being completed with ultrapure water up to a 1 mL final volume.

1 mL of samples, properly diluted, were spiked with 10 µL of internal standard and analyzed.

In order to study the precision and accuracy of the nicotine and cotinine determination in urine samples, urine blanks from a non-smoker were spiked per triplicate with a multi-analyte standard at various analyte concentration levels spanning a concentration range between 150 till 3800 ng mL⁻¹.

DHBMA, MHBMA, CEMA, 3-HPMA, CMEMA, and HMPMA analysis procedure

A Vanquish UHPLC chromatograph from Thermo Scientific (Waltham, MA, USA) was used with a triple quadrupole mass detector TSQ Altis from Thermo Scientific (Waltham, MA, USA). For the separation of the analytes, a Hypersil GOLD C18 column, 1.9 µm (150 × 2.1 mm), provided by Thermo Scientific (Waltham, MA, USA), was employed using a gradient of two mobile phases, ammonium formate (5mM) in 0.1% acetic acid in ultrapure water (A) and acetonitrile in HPLC-MS quality (B). The column temperature was 40°C. To perform the separation, the applied mobile phase gradient was as follows: 99.5 % (A) from the beginning to 0.5 min, then decreasing to 70 % (A) till 2 min,

maintaining 70% (A) till 7 min, followed by decreasing to 0% (A) at 8 min and maintaining 0% till 12 min, and finally, increasing the proportion of mobile phase A to 99.5% at 12.1 min and maintaining this proportion till the end of the program (18 min).

The detection of analytes was carried out using positive ionization (ESI⁺) by applying a voltage of 3500 V and negative ionization (ESI⁻) by applying a voltage of 3300 V. The injections were measured in cycles of 0.8 s, and the injection volume was 10 μ L. The *m/z* transitions used for the identification and quantification of the analytes and the ionization mode are indicated in Table S2.

A concentrated multi-analyte solution in water was prepared from commercial standards of the analytes. The calibration solutions were prepared in the concentration range between 9 and 750 ng mL^{-1} and made by mixing 100 μ L of non-smokers urine (urine blank), 20 μ L of 8 $\mu\text{g mL}^{-1}$ terfenadine, Val-Tyr-Val, triallyl phosphite, sulfaguanidine, sulfadimethoxine, reserpine, caffeine and acetaminophen multi-internal standard solution, and the appropriate volume of multi-analyte standard solution to reach the required concentration. Ultrapure water was added to reach a final volume of 1 mL.

One milliliter of properly diluted urine samples were spiked with 20 μ L of 20 $\mu\text{g mL}^{-1}$ of terfenadine, Val-Tyr-Val, triallyl phosphite, sulfaguanidine, sulfadimethoxine, reserpine, caffeine, and acetaminophen multi-internal standard solution of an adequate concentration and analyzed.

The precision and accuracy of analyte determination were established from three independent replicates of non-smoker urine blanks spiked at concentrations between 10 and 750 ng mL^{-1} and analyzed as unknown samples.

HS-GC/MS urine analysis

HS-GC-MS was used to determine the presence of acrylonitrile and crotonaldehyde due to their high volatility.

Acrylonitrile analysis

An Agilent Technologies 5975A GC System chromatograph (Palo Alto, CA, USA) equipped with a Zebron ZB-5MS 5% capillary column (30 m, 0.32 mm, 0.25 μm) and an Agilent Technologies 5975C inert XL EI/CI MSD triple axis simple quadrupole mass detector was used.

Acrylonitrile stock solutions were prepared in methyltetrahydrofuran (MeTHF) from pure acrylonitrile stock (>98%) (Darmstadt, Germany). As an internal standard, a solution of 1000 $\mu\text{g mL}^{-1}$ of acetonitrile in MeTHF was used, prepared from a 99.9% HPLC-grade acetonitrile provided by Scharlab (Barcelona, Spain). MeTHF 99% supplied by Pennakem (Memphis, TN, USA) was used to prepare all solutions. HS analysis was performed using glass vials with an internal

volume of 10 mL encapsulated with PTFE-silicone seals. Samples were injected into the chromatographic system using an Agilent Technologies 7697A Headspace sampler autosampler.

For the preparation of the calibration curve, solutions of the analyte with concentrations from 100 to 800 ng mL^{-1} were used, allowing a working range between 0.5 and 4 ng of acrylonitrile in urine samples. Ten microliters of the solutions of corresponding concentration were introduced into glass vials of 10 mL volume together with 5 μ L of the 1000 $\mu\text{g mL}^{-1}$ acetonitrile internal standard solution. Vials were capped and tested directly. Direct vaporization of acrylonitrile and internal standard was carried out at 90°C for 10 min. The gaseous fraction of the headspace was introduced through an injection loop of 1 mL volume at 95°C in split mode with a 1:8 ratio in the injector at 180°C, using a flow constant 1.3 mL min^{-1} of helium as carrier gas. Chromatographic separation was performed using an initial temperature of 60°C maintained for 6 min and increased with a ramp of 15°C min^{-1} until reaching 110°C. The transfer line and ionization source temperatures were 280 and 276°C, respectively.

The ionization of the analytes in the detector was performed using the electron impact (EI) mode at 70 eV, and the selected ion monitoring (SIM) was used for the acquisition of the signals of the analytes, registering the masses 53.1 *m/z* and 41.1 *m/z* for the quantification of acrylonitrile and acetonitrile, respectively.

Twenty microliters of urine samples was weighed with accuracy per triplicate with an analytical balance, and 5 μ L of the 1000 $\mu\text{g mL}^{-1}$ internal standard solution was added, encapsulated, and analyzed together with the standards.

Crotonaldehyde analysis

The determination of crotonaldehyde in urine samples was carried out according to the procedure proposed by Guo et al. [37]. For this purpose, an Agilent Technologies 5975A GC System chromatograph (Palo Alto, CA, USA) equipped with a Zebron ZB 5MS 5% capillary column (30 m, 0.32 mm, 0.25 μm) and an Agilent Technologies 5975C inert XL EI/CI MSD triple axis simple quadrupole mass detector was used.

Crotonaldehyde standard solutions were prepared in acetone from pure crotonaldehyde ($\geq 99\%$) (Darmstadt, Germany). As an internal standard, a solution of deuterated toluene (toluene-*d*₈) in acetone was used, prepared from deuterated toluene 99.9% Merck (Darmstadt, Germany). Acetone $\geq 99.9\%$ for GC residue analysis provided by Scharlau (Barcelona, Spain) was employed to prepare all solutions. HS analysis was performed using glass vials with an internal volume of 10 mL encapsulated with PTFE-silicone seals. Samples were injected into the chromatographic

system using an Agilent Technologies 7697A Headspace sampler autosampler. For the preparation of the calibration curve, solutions of the analyte with concentrations of 300 to 2500 ng mL⁻¹ were used, allowing the determination of crotonaldehyde in a range between 6 and 50 ng in samples. Five microliters of the standard solution with an adequate concentration was placed in glass vials of 10 mL volume together with 5 µL of the internal standard solution. The vials were capped and analyzed directly. Direct vaporization of acrylonitrile and internal standard were carried out at 90°C for 10 min. The gaseous fraction of the headspace was introduced through an injection loop of 1 mL volume at 95°C in split mode with a 1:8 ratio in the injector at 180°C, using a flow constant 1.3 mL min⁻¹ of helium as carrier gas. Chromatographic separation was performed using an initial temperature of 40°C maintained for 2 min and increased with a ramp of 2°C min⁻¹ until reaching 80°C. The transfer line and ionization source temperatures were 280 and 276°C, respectively.

The ionization of the analytes in the detector was performed using the electron impact (EI) mode at 70 eV, and the selected ion monitoring (SIM) was recorded at masses 41 m/z and 98 m/z for the quantification of crotonaldehyde and deuterated toluene, respectively.

The urine samples were weighed in triplicate on an analytical balance, placing 20 µL of each sample in glass vials with a volume of 10 mL. Five microliters of the internal standard solution were added, encapsulated, and analyzed in the same way as standards.

Statistical treatment

Descriptive statistics were calculated by employing the Sigma-Plot software package (Systat Software Inc., Chicago, IL, USA). Parameters as average and standard deviation, median, 95% confidence interval, minimum and maximum values, and the corresponding percentiles were calculated for each sample population and target analytes.

Results and discussion

Analytical features of employed methodologies

The supplementary material provides data about the method validation of employed procedures.

LC-MS/MS analysis of nicotine and cotinine

The linearity of the method was established from the calibration curves specified in the “[Nicotine and cotinine determination in samples](#)” section prepared in non-smokers urine. In all cases, satisfactory determination coefficients (R^2) were

found, finding values between 0.991 and 0.992. The limits of detection (LOD) and of quantification (LOQ) were determined as 3 and 10 times the intercept deviation divided by the slope. LOD values from 45 to 47 ng mL⁻¹ and LOQs between 134 and 144 ng mL⁻¹ were found for target analytes. Table S3 indicates the linearity and the LODs and LOQs values found.

Precision and accuracy of the analytical methodology were established from the recovery and RSD (%) of data corresponding to spiked urine (see Table S3). As can be seen, recovery values ranged between 93 and 104%, while RSD (%) values were in the range of 3 and 9%.

LC-MS/MS analysis of DHBMA, MHBMA, CEMA, 3-HPMA, CMEMA, and HMPMA

The method was validated in the same terms indicated before. The linearity provided determination coefficients (R^2) between 0.990 and 0.998. The limits of detection (LOD) and quantification (LOQ) were from 2.8 to 3.1 ng mL⁻¹ and LOQs between 9 and 11 ng mL⁻¹. Table S4 indicates the linearity and the values obtained for the LODs and LOQs of the analytes studied. Precision and accuracy of the analytical methodology were established from the recovery study and RSD (%) of spiked urine. Table S4 indicates values obtained. As can be seen, recoveries ranged between 87 and 104% and RSD (%) values lower than 7% were found.

HS-GC/MS analysis of acrylonitrile and crotonaldehyde

The acrylonitrile determination method was validated in terms of linearity, limits of detection and quantification, precision, and accuracy. The linearity was established from the calibration curves of the analytes in the concentration range between the limit of quantification and the loss of linearity in the analytical signal. In all cases, average determination coefficients (R^2) of 0.9951 were obtained. The limit of detection (LOD) and of quantification (LOQ) were determined from the calibration expressions as 3 and 10 times the intercept divided by the slope, obtaining values of 0.33 ng and 1.01 ng for LOD and LOQ, respectively. Table S3 indicates the linearity and the values obtained for the LOD and LOQ. Precision and accuracy were established from the RSD (%) values and recovery, respectively. Urine blanks from a non-smoker were spiked with a standard solution prepared in water at different acrylonitrile concentration levels and analyzed as unknown samples. Table S3 indicates the recovery and RSD (%) values obtained. The relative standard deviation values were lower than 11%, and the accuracy values found in a range between 84 and 99%.

Crotonaldehyde determination method has been validated in terms of linearity, limits of detection and quantification, precision, and accuracy. The linearity was established from

the calibration curves of the analytes in a concentration range between the limit of quantification and the loss of linearity in the analytical signal. In all cases, average determination coefficients (R^2) of 0.9951 were obtained. The limit of detection (LOD) and limit of quantification (LOQ) were determined from the calibration expressions as 3 and 10 times the intercept divided by the slope. A LOD value was established in 1.4 ng and the LOQ was 4.6 ng. Table S3 shows the linearity and the values obtained for the LOD and LOQ. The accuracy and precision of the analytical methodology were established from the recovery and RSD (%) values obtained. Urine blanks from non-smokers were spiked with a standard solution prepared in water at different crotonaldehyde concentration levels and analyzed as unknown samples. As can be seen, the RSD values were lower than 4%, with the recovery values which were in a range between 97 and 108%.

Analysis of urine samples

Nicotine and cotinine content in urine

Table 1 indicates the statistical analysis related to the concentrations found in urine. Nicotine concentration ranged from 80 to 9543 $\mu\text{g g}^{-1}$ creatinine for vapers consuming nicotine refilling solutions, while cotinine concentrations ranged from 302 to 17820 $\mu\text{g g}^{-1}$ creatinine (see Table S5 for statistics related to the concentrations found in urine). In all cases, cotinine levels reach higher values than the nicotine concentrations, thus indicating the nicotine metabolism to cotinine (Fig. 1). On the other hand, nicotine-free vapers eliminate nicotine from their organism being detected very low concentrations of cotinine in their urine. Nicotine and cotinine concentrations found in urine of active smokers were from 60 to 3562 $\mu\text{g g}^{-1}$ creatinine and from 276 to 5463 $\mu\text{g g}^{-1}$ creatinine, respectively. It can be seen that the nicotine/cotinine ratio varies for smokers and vapers.

Additional metabolomic studies should be required, as it has indicated recently by Hsiao et al. [38] in order to study possible differences in the metabolic route of nicotine in both populations. However, this study does not take into account the differences in the metabolism between individuals, and relative values to creatinine must be considered to avoid individual variabilities.

Furthermore, neither nicotine nor cotinine were detected in non-smokers not living with smokers. However, it must be highlighted the case of passive smokers. Nicotine and cotinine concentrations were detected in the initial steps of this study in urine of non-smoker living with active smokers at concentrations of 84 and 90 $\mu\text{g g}^{-1}$ creatinine and 64 to 74 $\mu\text{g g}^{-1}$ creatinine, respectively (see Table S5). These concentrations decreased until non-detected levels with the exposition cessation.

Table 1 Comparison of the descriptive statistics of nicotine and cotinine concentrations expressed as $\mu\text{g g}^{-1}$ creatinine in urine from non-smokers, smokers, and vapers

	Average \pm SD	Median	95% conf. interval	Min value	5th percentile	25th percentile	75th percentile	95th percentile	Max. value
Nicotine	Non-smokers	-	-	-	-	-	-	-	-
	Smokers	1170 \pm 1170	604	60	175	370	1648	3451	3565
Cotinine	Vapers	2100 \pm 2100	1479.5	80	159.5	854.5	2529.5	7375	9543
	Non-smokers	-	-	-	-	-	-	-	-
Cotinine	Smokers	2050 \pm 1450	2482.5	276	324	794.5	2811.5	3783.5	5463
	Vapers	4000 \pm 3300	3430	36	340	1770	5780	7791	17820




Fig. 1 Box plot of nicotine and cotinine concentrations found in vapers, smokers, and non-smokers urine. Note: insets show data excluding anomalous

Risk exposure marker determination: analysis of acrylonitrile and crotonaldehyde

Acrylonitrile and crotonaldehyde, as selected risk exposition markers, were determined in urine samples. Data obtained were lower than the respective methodology limit of detection (see Table S3), being non-detected and thus indicating the completely metabolization of these analytes.

Metabolite content in urine samples

Table 2 indicates the descriptive statistical analysis related to the concentration found of the targeted molecules in the analyzed urine samples.

3HPMA, a metabolite of acrolein, was found in the three sample classes evaluated, varying the concentrations range from non-detected to 2868 $\mu\text{g g}^{-1}$ creatinine for vapers' urine, from 735 till 3106 $\mu\text{g g}^{-1}$ creatinine for smokers, and from 167 to 2729 $\mu\text{g g}^{-1}$ creatinine for non-smokers.

HMPMA and CMEMA, both crotonaldehyde metabolites, were found in vapers' urine from non-detected to 2588 $\mu\text{g g}^{-1}$ creatinine, while a range from 881 to 4527 $\mu\text{g g}^{-1}$ creatinine in smokers and from 76 to 1829 $\mu\text{g g}^{-1}$ creatinine in non-smokers were determined. In the same way, CMEMA was found between 213 till 10989 $\mu\text{g g}^{-1}$ creatinine in vapers, from 116 to 6102 $\mu\text{g g}^{-1}$ creatinine in smokers, and from 76 till 3020 $\mu\text{g g}^{-1}$ creatinine in non-smokers.

On the other hand, acrylonitrile/1.3-butadiene metabolites DHBMA and MHBMA were detected in all analyzed samples. DHBMA concentrations in vapers' urine samples were from 58 till 961 $\mu\text{g g}^{-1}$ creatinine, while concentrations from 53 to 855 $\mu\text{g g}^{-1}$ creatinine and 144 to 977 $\mu\text{g g}^{-1}$ creatinine were found for smokers and non-smokers, respectively. In the same way, MHBMA concentrations spanned values from 36 $\mu\text{g g}^{-1}$ creatinine for all the urine classes till 396, 166, and 194 $\mu\text{g g}^{-1}$ creatinine for vapers, smokers, and non-smokers, respectively. CEMA acrylonitrile and acrolein metabolite

were only detected in smokers samples, in a concentration range from 41 to 266 $\mu\text{g g}^{-1}$ creatinine.

Comparison of metabolite concentrations in smokers, non-smokers and vapers' urine

Acrolein metabolites, 3HPMA Figure 2A indicates the comparison of 3HPMA concentrations, expressed in $\mu\text{g g}^{-1}$ creatinine, in the urine samples of vapers, smokers, and non-smokers.

As can be seen, four urine samples (6, 32, 57, and 83) showed abnormal high levels of 3HPMA. Regarding the rest of samples, it was observed that vaper levels were usually lower than in the case of smokers. Non-smokers had lowest concentrations, being the values found in agreement with the literature [39–42]. Furthermore, 3HPMA values for smokers and vapers were consistent with those reported by Higashi et al. [43] and Bjurlin et al. [44], respectively.

Crotonaldehyde metabolites, HMPMA, and CMEMA Figure 2C indicates the comparison of HMPMA concentrations found in urine of vapers, smokers, and non-smokers. As general trend, smokers' urine samples show the highest concentrations of HMPMA, with the exception of sample 6 and 83, both belonging to candidates suspected to alternate vaping with traditional tobacco use. This behavior is in good agreement with the reported data for dual users [45]. On the other hand, HMPMA values for non-smokers agree with those found in the literature [46] and are the same order of magnitude in urine of non-smokers and vapers [47].

Figure 2E shows the comparison of CMEMA concentrations found in urine of vapers, smokers, and non-smokers. It can be seen that concentrations in vapers' urine ranged between 213 and 10,990 $\mu\text{g g}^{-1}$ creatinine. These concentrations are higher than those reported by Frigerio et al. [48] for vapers' urine, which ranged from 154 to 542 $\mu\text{g g}^{-1}$ creatinine. On the contrary, non-smokers and smokers urine show in

Table 2 Comparison of the descriptive statistics of studied metabolites concentrations expressed as $\mu\text{g}_{\text{Creatinine}^{-1}}$ in urine from non-smokers, smokers, and vapers

		Average \pm SD	Median	95% conf. interval	Min value	5th percentile	25th percentile	75th percentile	95th percentile	Max. value
3HPMA	Non-smokers	610 \pm 570	365.5	223	167	210	267	724	1376	2729
	Smokers	2210 \pm 1275	1852	667	735	810.5	1286	2814	4480	4995
	Vapers	900 \pm 700	761.5	168	172	224.5	463	1197	2587	3037
CEMA	Non-smokers	-	-	-	-	-	-	-	-	-
	Smokers	180 \pm 80	169	52	41	53.5	102.5	262.5	302.5	370
HMPMA	Vapers	-	-	-	-	-	-	-	-	-
	Non-smokers	420 \pm 460	252	185	76	127	195	405.5	1663	1829
	Smokers	2970 \pm 1600	2960.5	833	881	945	1448	4159	5442	5650
MHBMA	Vapers	600 \pm 800	368.5	199	<LOQ	37.5	233	494	1461	5388
	Non-smokers	95 \pm 45	88.5	19	35	36.8	66.25	105.5	183.4	194
	Smokers	100 \pm 40	107	23	37	43	64	137.5	154	166
CMEMA	Vapers	130 \pm 80	110	19	31	44.5	79.5	157	303	396
	Non-smokers	800 \pm 715	572.5	286	114	145	373	913.5	2372	3020
	Smokers	1630 \pm 1985	863	1039	116	163	373	1809.5	6066	6102
DHBMA	Vapers	2250 \pm 2150	1459.5	526	213	337.5	820	370	5653	10,989
	Non-smokers	350 \pm 225	306	90	144	151	181.5	394.5	893	977
	Smokers	475 \pm 260	444	137	53	123	270	724	826.5	855
	Vapers	400 \pm 200	373	49	58	112	286	492	900	961




Fig. 2 Box plot of 3HPMA (A), CEMA (B), HMPMA (C), MHBMA (D), CMEMA (E), and DHBMA (F) concentrations found in vapers, smokers, and non-smokers urine. Note: insets show data excluding anomalous

general CMEMA concentrations in the same order of magnitude than that reported in the literature [46, 49]. So, although CMEMA is a secondary metabolite of crotonaldehyde, the behavior found in vapers' urine must be studied from a metabolomic viewpoint, especially when data obtained for HMPMA in vapers are at the same level than in non-smokers.

Acrylonitrile metabolites, MHBMA, DHBMA, and CEMA Figure 2D indicates the comparison of MHBMA concentrations found in urine from vapers, smokers, and non-smokers. The concentrations of MHBMA in vapers' urine were of the same order of magnitude or slightly higher than those found in smokers and non-smokers ones. It is reported that MHBMA can be from exogenous sources, being reflected by literature its presence in non-smokers. Thus, MHBMA concentrations found in urine of non-smokers and vapers were in good agreement with those found in literature [50].

Similar concentrations of DHBMA were found for the three groups of urine samples (see Fig. 2F). The concentration found in vapers compared with those of smokers

and non-smokers were similar, being this behavior previously reported [51].

CEMA was only detected on smokers and non-smokers exposed to burned tobacco (Fig. 2B). In this sense, those results were consistent with literature, being the CEMA concentrations in non-smokers and vapers' urine close to the quantification limits or lower than this limit, and reported concentration in smokers urine samples are about two order of magnitude higher than for non-smokers or vapers [46].

Conclusions

The present study has evidenced preliminary results on the prevalence of some metabolites of exposure toxicant markers related to diseases and cancer development in the urine of vapers, who in the past were strong smokers. It can be seen that CEMA metabolite is characteristic of tobacco smoke exposure/consumption, while the levels of HMPMA and MHBMA in urine from vapers are in the same order of magnitude than

those found for smokers or non-smokers. On the other hand, DHBMA in urine from vapers can reach similar values to those found for smokers. However, CMEMA shown concentrations in the urine of vapers are higher than those found for non-smokers and smokers. This fact can require a new research to link this metabolite with the use of electronic cigarettes and possible alternative metabolomic routes. In the spite of the potential presence in toxic substances in electronic cigarette aerosols, there is not enough data regarding the short- and long-term health effects of e-cigarettes, including cancer risk. In this sense, the electronic cigarettes cannot be considered a safe alternative to the traditional tobacco consumption.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00216-023-04943-w>.

Author contribution D. Gallart-Mateu: Conceptualization; methodology; validation; investigation; writing, original draft; review and editing

P. Dualde Marín: Conceptualization, methodology, validation, investigation, resources

C. Coscolla-Raga: Conceptualization, methodology, validation, investigation, resources, supervision

J.M. Soriano Llobera: Conceptualization, methodology, validation, investigation, resources, supervision, funding acquisition

S. Garrigues: Conceptualization, methodology, validation, investigation, resources, supervision, funding acquisition, writing — review

M. de la Guardia: Conceptualization, methodology, validation, investigation, resources, supervision, funding acquisition, writing — review

Funding Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. The present study has been co-funded by “Contrato de investigación ESPAÑA SALUD-UNIVERSITAT DE VALENCIA para el desarrollo del Proyecto: Evaluación de marcadores en orina de riesgo para la salud de fumadores que hayan reemplazado el Tabaco tradicional por HNB o vapeo” (CPI-21-147) and the European Union through the European Regional Development Fund Operational Programme (ERDF) of the Valencia Region (2014–2020). The European Commission financed the analytical instruments used here through the European Regional Development Funds (ERDF) Operation Program of the Valencian Region (2014–2020).

Declarations

Ethics approval The presented project was approved by Ethics Committee of the University of Valencia (Valencia, Spain), verification code X0H21EQATBAG6TVF.

Consent to participate Volunteers enrolled in the study have provided their written informed consent for the research study protocol.

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will

need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. World Health Organization, July 2021. <https://www.who.int/news-room/fact-sheets/detail/tobacco>. (last accessed on June 2023).
2. i-Sanidad, November 2020. <https://isanidad.com/173553/el-consu-mo-de-tabaco-ocasiona-cada-ano-en-espana-al-menos-69-000-muertes-prematuras>. (last accessed on June 2023).
3. GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. *Lancet*. 2017;389:1885–906. [https://doi.org/10.1016/S0140-6736\(17\)30819-X](https://doi.org/10.1016/S0140-6736(17)30819-X).
4. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021;71(3):209–49. <https://doi.org/10.3322/caac.21660>.
5. US Department of Health and Human Services. The health consequences of smoking — 50 years of progress. A Report of the Surgeon General (US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014. (last accessed on June 2023).
6. International Agency for Research on Cancer. Personal habits and indoor combustions. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Vol. 100E. <https://publications.iarc.fr/Book-And-Report-Series/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans/Personal-Habits-And-Indoor-Combustions-2012>. (last accessed on June 2023).
7. Goniewicz ML, Kuma T, Gawron M, Knysak J, Kosmider L. Nicotine levels in electronic cigarettes. *Nicotine Tob Res*. 2013;15:158–66. <https://doi.org/10.1093/ntr/nts103>.
8. Schripp T, Markewitz D, Uhde E, Salthammer T. Does e-cigarette consumption cause passive vaping? *Indoor Air*. 2013;23:25–31. <https://doi.org/10.1111/j.1600-0668.2012.00792.x>.
9. Sleiman M, Logue JM, Montesinos VN, Russell ML, Litter MI, Gundel LA, Destailhats H. Emissions from electronic cigarettes: key parameters affecting the release of harmful chemicals. *Environ Sci Technol*. 2016;50:9644–51. <https://doi.org/10.1021/acs.est.6b01741>.
10. Uchiyama S, Ohta K, Inaba Y, Kunugita N. Determination of carbonyl com- pounds generated from the E-cigarette using coupled silica cartridges impregnated with hydroquinone and 2,4-dinitrophenylhydrazine, followed by high-performance liquid chromatography. *Anal Sci*. 2013;29:1219–22. <https://doi.org/10.2116/analsci.29.1219>.
11. Casanova-Cháfer J, Gallart-Mateu D, Armenta S, de la Guardia M. Preliminary results about the breath of passive smokers and vapers based on the use of portable air monitoring devices. *Microchem J*. 2016;126:454–9. <https://doi.org/10.1016/j.microc.2016.01.004>.
12. Lim HH, Shin HS. Determination of volatile organic compounds including alcohols in refill fluids and cartridges of electronic cigarettes by headspace solid-phase micro extraction and gas chromatography-mass spectrometry. *Anal Bioanal Chem*. 2017;409:1247–56. <https://doi.org/10.1007/s00216-016-0049-0>.
13. Varlet V, Farsalinos K, Augsburger M, Thomas A, Etter JF. Toxicity assessment of refill liquids for electronic cigarettes. *Int J Environ Res Public Health*. 2015;12:4796–815. <https://doi.org/10.3390/ijerph120504796>.

14. Goniewicz ML, Knysak J, Gawron M, Kosmider L, Sobczak A, Kurek J, Prokopowicz A, Jablonska-Czapla M, Rosik-Dulewska C, Havel C, Jacob P, Benowitz N. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. *Tob Control*. 2014;23:133–9. <https://doi.org/10.1136/tobaccocontrol-2012-050859>.
15. Tang MS, Wu XR, Lee HW, Xia Y, Deng FM, Moreira AL, Chen LC, Huang WC, Lopor H. Electronic-cigarette smoke induces lung adenocarcinoma and bladder urothelial hyperplasia in mice. *Proc Natl Acad Sci U S A*. 2019;116(43):21727–31. <https://doi.org/10.1073/pnas.1911321116>.
16. Tommasi S, Blumenfeld H, Besaratinia A. Vaping dose, device type, and e-liquid flavor are determinants of DNA damage in electronic cigarette users. *Nicotine Tob Res*. 2023;25(6):1145–54. <https://doi.org/10.1093/ntr/ntad003>.
17. International Agency for Research on Cancer. Chemical agents and related occupations, IARC Monogr Eval Carcinog Risks Hum. 2012;100:9–562. <https://publications.iarc.fr/Book-And-Report-Series/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans/Chemical-Agents-And-Related-Occupations-2012>. (last accessed on June 2023).
18. Bahadar H, Mostafalou S, Abdollahi M. Current understandings and perspectives on non-cancer health effects of benzene: a global concern. *Toxicol Appl Pharmacol*. 2014;276:83–94. <https://doi.org/10.1016/j.taap.2014.02.012>.
19. Galbraith D, Gross SA, Paustenbach D. Benzene and human health: a historical review and appraisal of associations with various diseases. *Crit Rev Toxicol*. 2010;40(2):1–46. <https://doi.org/10.3109/10408444.2010.508162>.
20. Filley CM, Halliday W, Kleinschmidt-DeMasters BK. The effects of toluene on the central nervous system. *J Neuropathol Exp Neurol*. 2004;63:1–12. <https://doi.org/10.1093/jnen/63.1.1>.
21. Sielken RL, Valdez-Flores C. A comprehensive review of occupational and general population cancer risk: 1,3-butadiene exposure-response modeling for all leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, myeloid neoplasm and lymphoid neoplasm. *Chem Biol Interact*. 2015;241:50–8. <https://doi.org/10.1016/j.cbi.2015.06.009>.
22. Semla M, Goc Z, Martiniaková M, Omelka R, Formicki G. Acrylamide: a common food toxin related to physiological functions and health. *Physiol Res*. 2017;66:205–17. <https://doi.org/10.33549/physiolres.933381>.
23. Hecht SS. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. *Carcinogenesis*. 2002;23:907–22. <https://doi.org/10.1093/carcin/23.6.907>.
24. Messina ES, Tyndale RF, Sellers EM. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. *J Pharmacol Exp Ther*. 1997;282(3):1608–14.
25. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, Kuroiwa Y. Characterization of CYP2A6 involved in 30-hydroxylation of cotinine in human liver microsomes. *J Pharmacol Exp Ther*. 1996;277(2):1010–5.
26. Avila-Tang E, al-Delaimy WK, Ashley DL, Benowitz N, Bernert JT, Kim S, Samet JM, Hecht SS. Assessing secondhand smoke using biological markers. *Tob Control*. 2013;22(3):164–71. <https://doi.org/10.1136/tobaccocontrol-2011-050298Baidoo>.
27. Benowitz NL, Jacob P 3rd, Fong I, Gupta S. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. *J Pharmacol Exp Ther*. 1994;268(1):296–303.
28. Dempsey D, Tutka P, Jacob P, Allen F, Schoedel K, Tyndale RF, Benowitz NL. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. *Clin Pharmacol Ther*. 2004;76(1):64–72. <https://doi.org/10.1016/j.clpt.2004.02.011>.
29. Malkawi AH, Al-Ghananeem AM, de Leon J, Crooks PA. Nicotine exposure can be detected in cerebrospinal fluid of active and passive smokers. *J Pharm Biomed Anal*. 2009;49(1):129–32. <https://doi.org/10.1016/j.jpba.2008.10.003>.
30. Torres S, Merino C, Paton B, Correig X, Ramirez N. Biomarkers of exposure to secondhand and thirdhand tobacco smoke: recent advances and future perspectives. *Int J Environ Res Public Health*. 2018;15(12):2693–2693. <https://doi.org/10.3390/ijerph15122693>.
31. Benowitz NL, Hukkanen J, Jacob P. Nicotine chemistry, metabolism, kinetics and biomarkers. In: Henningfield JE, London ED, Pogun S, editors. *Nicotine psychopharmacology, Handbook of Experimental Pharmacology*, Springer 2009, 192, pp. 29–60. https://doi.org/10.1007/978-3-540-69248-5_2.
32. De Rooij BM, Commandeur JNM, Vermeulen NPE. Mercapturic acids as biomarkers of exposure to electrophilic chemicals: applications to environmental and industrial chemicals. *Biomarkers*. 1998;3:239–303. <https://doi.org/10.1080/135475098231101>.
33. Parkinson A, Ogilvie W. Biotransformation of xenobiotics. In: M.G. Klaassen CD, Watkins III JB, editors. *Casarett & Doull's Essentials of Toxicology*, 3e. McGraw Hill; 2015.
34. Perbellini L, Veronese N, Princivalle A. Mercapturic acids in the biological monitoring of occupational exposure to chemicals. *J Chromatogr B Anal Technol Biomed Life Sci*. 2002;781:269–90. [https://doi.org/10.1016/S1570-0232\(02\)00501-9](https://doi.org/10.1016/S1570-0232(02)00501-9).
35. Habibagahi A, Alderman N, Kubwabo C. A review of the analysis of biomarkers of exposure to tobacco and vaping products. *Anal Methods*. 2020;12:4276–302. <https://doi.org/10.1039/D0AY01467B>.
36. Jaffe M. Ueber den Niederschlag, welchen Pikrinsäure in normalem Harn erzeugt und über eine neue Reaction des Kreatinins. *Biol Chem*. 1886;10(5):391–400. <https://doi.org/10.1515/bchm1.1886.10.5.391>.
37. Guo X, Stolee JA, Fillon YA, Zou L. Trace-level determination of acrylonitrile generated in the manufacturing process of oligonucleotides by static headspace gas chromatography with an electron impact(+) mass detector. *Org Process Res Dev*. 2021;25(2):318–26. <https://doi.org/10.1021/acs.oprd.0c00527>.
38. Hsiao YC, Matulewicz RS, Sherman SE, Jaspers I, Weitzman ML, Gordon T, Liu CW, Yang Y, Lu K, Bjurlin MA. Untargeted metabolomics to characterize the urinary chemical landscape of e-cigarette users. *Chem Res Toxicol*. 2023;36(4):630–42. <https://doi.org/10.1021/acs.chemrestox.2c00346>.
39. Cravo AS, Bush J, Sharma G, Savioz R, Martin C, Craige S, Walele T. A randomised, parallel group study to evaluate the safety profile of an electronic vapour product over 12 weeks. *Regul Toxicol Pharmacol*. 2016;81(1):S1–14. <https://doi.org/10.1016/j.yrtph.2016.10.003>.
40. Sakaguchi C, Kakehi A, Minami N, Kikuchi A, Futamura Y. Exposure evaluation of adult male Japanese smokers switched to a heated cigarette in a controlled clinical setting. *Regul Toxicol Pharmacol*. 2014;69(3):338–47. <https://doi.org/10.1016/j.yrtph.2014.04.016>.
41. Morin A, Shepperd CJ, Eldridge AC, Poirier N, Voisine R. Estimation and correlation of cigarette smoke exposure in Canadian smokers as determined by filter analysis and biomarkers of exposure. *Regul Toxicol Pharmacol*. 2011;61(3):S3–12. <https://doi.org/10.1016/j.yrtph.2010.09.020>.
42. Shepperd CJ, Shepperd CJ, Eldridge AC, Mariner DC, McEwan M, Errington G, Dixon M. A study to estimate and correlate cigarette smoke exposure in smokers in Germany as determined by filter analysis and biomarkers of exposure. *Regul Toxicol Pharmacol*. 2009;55(1):97–109. <https://doi.org/10.1016/j.yrtph.2009.06.006>.
43. Higashi K, Igarashi K, Toida T. Recent progress in analytical methods for determination of urinary 3-hydroxypropylmercapturic acid, a major metabolite of acrolein. *Biol Pharm Bull*. 2016;39(6):915–9. <https://doi.org/10.1248/bpb.b15-01022>.
44. Bjurlin MA, Matulewicz RS, Roberts TR, Dearing BA, Schatz D, Sherman S, Gordon T, El Shahawy O. Carcinogen biomarkers in the urine of electronic cigarette users and implications for the

- development of bladder cancer: a systematic review. *Eur Urol Oncol.* 2021;4(5):766–83. <https://doi.org/10.1016/j.euo.2020.02.004>.
45. Goniewicz ML, Smith DM, Edwards KC, Blount BC, Caldwell KL, Feng J, Wang L, Christensen C, Ambrose B, Borek N, Van Bommel D, Konkel K, Erives G, Stanton CA, Lambert E, Kimmel HL, Hatsukami D, Hecht SS, Niaura RS, Travers M, Lawrence C, Hyland AJ. Comparison of nicotine and toxicant exposure in users of electronic cigarettes and combustible cigarettes. *JAMA Netw Open.* 2018;1(8):e185937. <https://doi.org/10.1001/jamanetworkopen.2018.5937>.
46. Frigerio G, Mercadante R, Campo L, Polledri E, Boniardi L, Olgiati L, Missineo P, Fustinoni S. Urinary biomonitoring of subjects with different smoking habits. Part I: Profiling mercapturic acids. *Toxicol Lett.* 2020;327:48–57. <https://doi.org/10.1016/j.toxlet.2020.03.010>.
47. Chen M, Carmella SG, Lindgren BR, Luo X, Ikuemonisan J, Niesen B, Thomson NM, Murphy SE, Hatsukami DK, Hecht SS. Increased levels of the acrolein metabolite 3-hydroxypropyl mercapturic acid in the urine of e-cigarette users. *Chem Res Toxicol.* 2023;36(4):583–8. <https://doi.org/10.1021/acs.chemrestox.2c00145>.
48. Frigerio G, Mercadante R, Polledri E, Missineo P, Campo L, Fustinoni S. An LC-MS/MS method to profile urinary mercapturic acids, metabolites of electrophilic intermediates of occupational and environmental toxicants. *J Chromatogr B.* 2019;1117:66–76. <https://doi.org/10.1016/j.jchromb.2019.04.015>.
49. Pal VK, Li AJ, Zhu H, Kannan K. Diurnal variability in urinary volatile organic compound metabolites and its association with oxidative stress biomarkers. *Sci Total Environ.* 2022;818:151704. <https://doi.org/10.1016/j.scitotenv.2021.151704>.
50. Urban M, Gilch G, Schepers G, van Miert E, Scherer G. Determination of the major mercapturic acids of 1,3-butadiene in human and rat urine using liquid chromatography with tandem mass spectrometry. *J Chromatogr B.* 2003;796(1):131–40. <https://doi.org/10.1016/j.jchromb.2003.08.009>.
51. Lorkiewicz P, Riggs DW, Keith RJ, Conklin DJ, Xie Z, Sutaria S, Lynch B, Srivastava S, Bhatnagar A. Comparison of urinary biomarkers of exposure in humans using electronic cigarettes, combustible cigarettes, and smokeless tobacco. *Nicotine Tob Res.* 2019;21(9):1228–38. <https://doi.org/10.1093/ntr/nty089>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.